Children With Autism Spectrum Disorder With Regression Exhibit a Different Profile in Plasma Cytokines and Adhesion Molecules Compared to Children Without Such Regression by Gómez-Fernández, Antonio et al.
ORIGINAL RESEARCH
published: 26 September 2018
doi: 10.3389/fped.2018.00264
Frontiers in Pediatrics | www.frontiersin.org 1 September 2018 | Volume 6 | Article 264
Edited by:
Paolo Curatolo,




Università degli Studi di Roma Tor
Vergata, Italy
Romina Moavero,






This article was submitted to
Pediatric Neurology,
a section of the journal
Frontiers in Pediatrics
Received: 03 July 2018
Accepted: 05 September 2018
Published: 26 September 2018
Citation:
Gomez-Fernandez A,
de la Torre-Aguilar MJ, Gil-Campos M,
Flores-Rojas K, Cruz-Rico MD,
Martin-Borreguero P and
Perez-Navero JL (2018) Children With
Autism Spectrum Disorder With
Regression Exhibit a Different Profile in
Plasma Cytokines and Adhesion




Children With Autism Spectrum
Disorder With Regression Exhibit a
Different Profile in Plasma Cytokines
and Adhesion Molecules Compared
to Children Without Such Regression
Antonio Gomez-Fernandez 1, Maria J. de la Torre-Aguilar 1, Mercedes Gil-Campos 2*,
Katherine Flores-Rojas 2, Maria D. Cruz-Rico 3, Pilar Martin-Borreguero 4 and
Juan Luis Perez-Navero 1
1Department of Pediatrics, Reina Sofia University Hospital, University of Córdoba, Maimónides Institute for Biomedical
Research of Córdoba (IMIBIC), Cordoba, Spain, 2 Pediatric Metabolism Unit, Reina Sofia University Hospital, Maimónides
Institute for Biomedical Research of Córdoba (IMIBIC), University of Córdoba, Centro de Investigación Biomédica en
Red-Fisiopatología de la Obesidad y Nutrición (CIBEROBN), Cordoba, Spain, 3Department of Biochemistry and Molecular
Biology II, Institute of Nutrition and Food Technology, Center of Biomedical Research, University of Granada, Granada, Spain,
4Department of Child and Adolescent Clinical Psychiatry and Psychology, Reina Sofia University Hospital, Maimónides
Institute for Biomedical Research of Córdoba (IMIBIC), Cordoba, Spain
Background: In the etiopathogenesis of autism spectrum disorder (ASD), it has
been suggested that a proinflammatory condition, as well as an alteration in
adhesion molecules in the early stages of neurodevelopment, may play a role in the
pathophysiology of the disorder. This study set out to evaluate the plasma levels of certain
inflammatory cytokines, adhesion molecules, and growth factors in a sample of pediatric
patients with ASD and compare them to the levels in a control group of healthy children.
Methods: Fifty-four children (45males and nine females) aged 2-6, who were diagnosed
with ASD, and a control group of 54 typically-developing children of similar ages were
selected. The diagnosis of ASD was carried out in accordance with the DSM-5 criteria
and the data obtained from a developmental semi-structured clinical interview and
the ADOS evaluation test. Additional testing was carried out to identify the children’s
developmental level and severity of ASD symptomatology. Patients with ASDwere further
divided into two subgroups based on developmental parameters: ASD children with
neurodevelopmental regression (AMR) and ASD children without neurodevelopmental
regression (ANMR). Analyses of plasma molecules, such as cathepsin, IL1β, IL6, IL8,
MPO, RANTES, MCP, BDNF, PAI NCAM, sICAM, sVCAM and NGF, were performed.
Results: Higher levels of NGF were observed in the ASD group compared with the
levels in the control group (p < 0.05). However, in the analysis of the ASD subgroups,
lower plasma levels of NCAM and higher levels of NGF were found in the group of
ASD children without developmental regression compared to the levels in the group of
typically-developing children.
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Conclusions: These results suggest differences that could be related to different
pathophysiological mechanisms in ASD. There is not a specific profile for the expression
of relevant plasma cytokines, adhesion molecules or growth factors in children with
ASD compared with that in typically-developing children. However, in the ANMR and
AMR subgroups, some of the adhesion molecules and neuronal growth factors show
differences that may be related to synaptogenesis.
Keywords: autism spectrum disorder, cell adhesion molecules, children, cytokines, neurodevelopmental
regression
INTRODUCTION
Autism spectrum disorder (ASD) is a neurodevelopmental
disorder that is characterized by persistent deficits in social
communication and social interaction across multiple contexts
and by the presence of repetitive and restricted patterns of
behaviors, activities, and interests. These deficits are present from
early childhood, although some difficulties may not manifest
themselves until the demands of the environment exceed the
capacity of the child (1). ASD mainly affects males, by a ratio of
4:1 (2), and is generally detected in the second year of life.
It is well established that children with ASD do not
constitute a homogeneous clinical group, and many different
pathologies show a similar constellation of behavioral symptoms
that converge within ASD. The existence of developmental
regression in some children with ASD has been corroborated
by multiple studies (3). Children with ASD who lose skills
belong to a subgroup designated with the term “regressive
autism.” Regressive autism usually refers to a child whose
parents report an early history of normal development for 12–
24 months, followed by a loss of previously acquired skills.
Language regression is the most obvious form of regression,
but regressive autism can also be accompanied by more global
regression involving loss of social attention, social skills and
social interest (4).
Knowledge about the etiology and neuropathology of ASD
remains elusive however, and no biological markers have been
found. Most studies concur that there has been a significant
increase in the prevalence of autism, affecting approximately
0.75–1.55% of the pediatric population (5, 6). It has recently been
reported that the prevalence of ASD reaches nearly 3% in some
communities in the United States, representing an increase of
150% since 2000 (7).
Various studies published in recent years have supported the
idea that a proinflammatory situation may play a role in the
pathophysiology of ASD (8). An increase in proinflammatory
Abbreviations: ASD, Autism Spectrum Disorder; AMR, mental regression
group; ANMR, non-mental regression group; BDNF, brain derived neurotrophic
factor; BMI, Body mass index; CARS, Childhood Autism Rating Scale Test;
C-CRP, C-reactive protein HGF, hepatocyte growth factor; ICAM, intercellular
adhesion molecule; IL, interleukin; MCP-1, monocyte chemotactic protein; MPO,
myeloperoxidase; NCAM, neuronal cell adhesion molecules; NGF, nerve growth
factor; PAI, plasminogen activator factor; PDDBI, PDD Behavior Inventory;
RANTES, regulated on activation normal t cell expressed and secreted; TNFα,
tumor necrosis factor α; VCAM, vascular cell adhesion molecules.
cytokines has been reported in samples of post-mortem brain
tissue and cerebrospinal fluid, plasma, and mononuclear cell
cultures (9, 10). Levels of tumor necrosis factor alpha (TNF-α),
interleukins 6 and 8 (IL-6, IL-8), monocyte-macrophage colony
stimulating factor (GM-CSF) and interferon gamma (IFN-γ)
have also been reported as being higher in the brains of patients
with ASD than in the brains of the healthy population (11).
The increase in cytokines may indicate an impaired immune
response, with a predominant response of Th2 cells. Some
authors have suggested the existence of an endophenotype of
ASD linked to an autoimmune dysregulation (12). Others (13, 14)
have described altered levels of immune mediators linked to
greater deterioration in behavior. It has thus been suggested that
a dysregulation of the immune response may be related to the
behavior and cognitive impairment of children with ASD.
Chemokines and their receptors have been implicated in the
circulation and movement of mononuclear cells in the CNS,
mediating the recruitment of myeloid cells into areas of damage
and inflammation. Increased levels of various chemokines
(macrophage inflammatory proteins [MIP-1B], regulated on
activation, normal T cell expressed and secreted [RANTES],
monocyte Chemoattractant protein-1 [MCP-1]) have been
reported in astrocytes in the cerebellum and brain tissue,
as well as in peripheral blood in children with ASD. They
have been linked to a deterioration in communication skills,
stereotyped behaviors and hyperactivity, and an impairment of
cognitive functions and adaptive skills (15, 16). The cell adhesion
molecule is an Ig superfamily adhesion molecule (CAM) with an
established role in axon growth and repulsion. Serum samples
have been reported to exhibit a decrease in the levels of vascular
and intercellular cell adhesion molecules, notably sPECAM-
1 (soluble platelet-endothelial cell adhesion molecule-1) and
sVCAM-1 (soluble vascular cell adhesion molecule-1), which can
also play a role in the development of ASD (17).
Multiple hypotheses have been put forward to account for
the etiopathogenesis and developmental trajectories of ASD. The
roles of cytokines, adhesion molecules and growth factors have
not been clarified precisely in this regard, but they may have an
adverse bearing on the establishment of neuronal synapses and
their functioning in a situation of greater synaptic plasticity. The
goal of the present study was therefore to analyze the plasma
levels of some relevant molecules in children with ASD and to
compare these to the values exhibited by a group of typically-
developing children. The study also focused on the possible
relationships between the levels of such cytokines and the
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clinical severity of ASD core symptomatology and the regression
phenotype in ASD.
MATERIALS AND METHODS
This observational case-control study was approved by the
Clinical Research and Bioethics Committee at the authors’
hospital and was conducted in full compliance with the
fundamental principles established in the Declaration of
Helsinki. The data relating to the ASD patients were collected at
the time they were recruited into the study. The selected subjects
were incorporated into the study after all the criteria for inclusion
were fulfilled, and informed written consent was obtained from
the children’s legal guardians.
Subjects
The patients with ASD were recruited from the Department of
Child and Adolescent Clinical Psychiatry and Psychology at the
authors’ hospital. Some of the patients (aged 2–3) were recruited
at the time of their ASD diagnosis, whereas the older patients
(aged 3–6) were selected from among those who had already
been diagnosed at the same unit. The control group comprised
children diagnosed with phimosis and hernias, lacking any other
pathology, who attended preoperative anesthesia consultations
prior to surgical corrections. None of the controls belonged to
the same families as the ASD cases.
The diagnosis of ASD was based on the clinical judgment
of professionals specialized in the identification of the unique
developmental profile of subjects with ASD. The diagnostic
decision was based on the information obtained from semi-
structured clinical development interviews and psychological and
behavioral tests internationally recognized as reliable and valid
for this purpose. In this study, two clinical psychologists, a
psychiatrist and an occupational therapist with extensive clinical
experience and training in diagnostic tests for research in ASD
performed the diagnosis using the criteria established by DSM-5
(1). Two specialized pediatricians reviewed the medical histories
of the children and performed examinations of all the children.
Inclusion criteria: the ASD children were 2–6 years old with
a clinical diagnosis confirmed by validated scores. Additionally,
a control group of typically-developing children was selected
and matched to the ASD group by gender and age. A physical
examination, assessing neurological development and a blood
analysis were performed to confirm that they were healthy
children.
Any children with ASD presenting other neurological,
metabolic or genetic diagnoses were excluded, as were children
receiving medical treatment for autism-related behavioral
comorbidities. The group of ASD children was further divided
into two subgroups based on the presence or absence of
neurodevelopmental regression during the first two years of life,
which was assessed using a five-item questionnaire following
the guidelines used by the Autism Diagnostic Interview-Revised
(ADI-R) for the evaluation of this process (18). The ASD
children who obtained a score equal to or >3 were included
in the neurodevelopmental regression ASD group (AMR), and
those with a score of less than 3 were included in the non-
neurodevelopmental regression ASD group (ANMR). The ASD
group was also classified according to whether children presented
neurodevelopmental delay (i.e., a score lower than 70 in the
cognitive quotient of the Battelle developmental test).
Standardized Diagnostic Measurements
and Assessments of ASD Severity
All the children with ASD underwent an initial developmental
clinical interview, which identified the core symptomatology
of ASD according to DSM-5 clinical diagnostic criteria.
Additionally, the following tests were administered to all the
children:
a) Autism Diagnostic Observation Schedule-2 (ADOS-2) (19).
This is a standardized and semi-structured assessment scale
designed to measure communication, social interaction, play,
and the imaginative use of materials. The children were given
an ADOSmodule consistent with their language development
and age. This was administered by two clinical psychologists
with official formal training in the administration and
quantitative interpretation of the test for research purposes.
All children with ASD in the study exceeded the cut-off point
for the diagnosis of ASD.
b) Pervasive Developmental Disorders Behavior Inventory
Parent Ratings (PDDBI), standardized version for the
Spanish-speaking European population. (20) This test was
used to evaluate the symptomatic severity of pervasive
developmental disorders in ASD patients aged from 2 to 6
years. This test, which was administered to all the parents (not
teachers) of the children with ASD, evaluates the characteristic
ASD core behavioral deficit (deficits in social interaction,
language and pragmatic communication and stereotyped
behavior), additional behavioral difficulties (fears, aggressive
behaviors), and adaptive behaviors (scales of the children’s
social, linguistic, and learning skills). All the children with
ASD in the study obtained a score ≥30.
c) Childhood Autism Rating Scale Test (CARS-2) (21). This
scale was used for the quantification of the severity of autism
pathology: mild, moderate or severe.
d) Battelle Developmental Inventory, Second Edition (BDI-2)
(22). This test assesses the child’s current level of development
and functioning in five areas (i.e., personal/social, adaptive,
motor, communication, and cognitive areas).
e) Strengths and Difficulties Questionnaire (SDQ) (23): Two to
four years. This questionnaire was used to assess the presence
of behavioral difficulties, as well as adaptive behaviors.
Clinical Evaluation
A thorough developmental clinical history, including major
childhood illnesses and immunisations, was taken. A physical
examination was also conducted with a special emphasis
on neurological and nutritional status. Anthropometric
measurements (weight, height and body mass index) were
obtained using standard techniques, and validated nutritional
questionnaires were also administered.
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Biochemical Analysis
After overnight fasting, blood samples were collected from
the children with ASD and the healthy controls from the
antecubital vein into 6-ml blood collection tubes containing
EDTA. After centrifugation at 3,500 g for 10min, plasma
was divided into aliquots and processed within 2 h from
sampling, and then frozen at −80◦C until analysis. Blood
count and a general biochemical analysis were performed to
confirm the absence of other diseases. C-reactive protein (C-
CRP) (mg/l) was also measured as an inflammatory marker.
These analyses were performed in the hospital laboratory
using colorimetric, enzymatic, kinetic, indirect potentiometry,
or immunoturbidimetric methods previously standardized,
using an automatic autoanalyzer (Roche-Hitachi Modular PYD
autoanalyzer, Roch Laboratory Systems, Mannheim, Germany).
In the light of observations made in the existing literature
(24, 25), molecules that have previously been linked to autism
were selected for plasma analysis: IL-1beta, IL-6 and IL-8,MCP-1,
TNF-α, myeloperoxidase (MPO), RANTES, cathepsin D, brain-
derived neurotrophic factor (BDNF), hepatocyte growth factor
(HGF), nerve growth factor (NGF), plasminogen activator factor
(PAI) and cell adhesion molecule (NCAM, sICAM, VCAM).
These biomarkers were analyzed through simultaneous
detection of multi-analytes using LINCOplex assay kits and
Luminex xMAP Detection Technology. The sensitivity of this
assay enabled the detection of chemokine concentrations to the
following concentrations: IL1-β, 0.4183 pg/ml; IL-6, 0.2 pg/ml;
IL-8, 0.3 pg/ml; MCP-1, 2 pg/ml; TNF-α, 0.3 pg/ml; MPO, 20
ug/L; cathepsin D, 8.06 ug/L; RANTES: 12 ug/L; BDNF, 0.23
ug/L; HGF, 4 pg/ml; NGF, 0.3 pg/ml; plasminogen activator factor
(PAI), 0.48 ug/L; NCAM, 4.81 ug/L; sICAM-1, 6.29 ug/L, and
sVCAM, 6.44 ug/L).
Statistical Analysis
With regard to the size of the ASD sample used in this study,
given that the prevalence of ASD in Spain is calculated at 1%
(5), 50 patients with ASD needed to be recruited for the study,
taking into account a 5% margin of errors and a 95% confidence
interval. The sample size for this study was calculated based on
the most relevant inflammatory parameters using published data
results (16), choosing the one that required a larger sample size
(RANTES). Accepting alpha errors of 0.05 and beta errors of
0.2 in a bilateral contrast, 54 subjects per group were required
to detect a difference equal to or >400 pg/ml. The standard
deviation was assumed to be 720.
The values of the molecules that were not detected were
considered to be lost values, and the statistical study was
performed on the remaining values. The data are expressed
as mean ± SD (95% confidence intervals), median (IQR) or
absolute (relative frequencies). The Shapiro–Wilk test was used
for typically distributed data. Homogeneity of variances was
estimated using Levene’s test. The mean values for typically-
distributed continuous variables among groups were compared
using the unpaired Student’s t-test. The Mann–Whitney U-
test was used for asymmetrically distributed data. Bonferroni
correction was used for multiple comparisons to avoid chance.
Categorical variables were assessed using the χ²-test or the Fisher
exact test.
Comparisons between subgroups of ASD and with the control
group were performed using ANOVA, with the Sidak correction
for post hoc comparisons. Correlations between the biomarker
levels and the scores resulting from the various tests carried out
were performed using Spearman’s p (rho). All the tests were two-
tailed, and a P-value <0.05 was considered to be statistically
significant. The data were analyzed using the Statistical Package
for the Social Sciences (SPSS for Windows, release 18.0.0 2010,
SPSS Inc, Chicago, IL, USA).
RESULTS
Initially, 57 ASD children were selected for this study. Of these,
three children were later excluded for not meeting the diagnostic
criteria for ASD during the subsequent follow-up interviews at
30 months. The clinical and psychological characteristics of the
ASD patients, the subgroup with neurodevelopmental regression
(AMR) and subgroup without neurodevelopmental regression
(ANMR) and the typically-developing controls are shown in
Table 1. Within the ASD group, there were 20 children included
in the AMR subgroup and 32 in the ANMR subgroup; two
children could not be classified in these subgroups because they
were adoptees, allocated by a national adoption agency. Clinical
differences between these two ASD subgroups were reflected in
the different behavioral tests scores obtained. All the children
obtained scores above the ASD cut-off point in the ADOS-2
test. However, the patients in the AMR subgroup obtained lower
scores in the Battelle developmental test than those in the ANMR
subgroup, as well as higher scores in the CARS-2 test and total
autism severity score in the PDBB test (Table 1).
All the proinflammatory biomarkers were detected in the
plasma samples of more than 50% of the children with ASD,
except for IL1β, which was detected in the plasma of only 16%
of children with ASD and 6% of typically-developing children
(χ²: 2,7; p: 0.141), and NGF, which was detected in 37% of
children with ASD and 27% of the control children (χ²: 1,77;
p: 0.183). No differences were found between the two groups
in terms of the cytokine and adhesion molecule levels studied,
except for NGF, in which the group of ASD children was found
to have twice the plasma levels compared to the control group
(Table 2).
Within the ASD group, the ANMR subgroup had lower
NCAM plasma levels than both the AMR subgroup and
typically-developing children, and higher NGF levels than the
typically-developing children in the control group (Figure 1).
There was no association between NCAM and NGF levels
in any of the groups. There was no correlation between
the levels of NCAM and NGF in either ASD subgroup,
whether AMR or ANMR. No differences were identified in
the levels of the molecules when comparing ASD subgroups
either between high and low-functioning ASD children (in
accordance with the cognitive scores from the Battelle test),
or between female and male ASD children (results not
shown).
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TABLE 1 | Demographic and anthropometric data in children with autism spectrum disorders (ASD) compared to controls.
ASD CONTROL P
Total AMR ANMR









Gender (male) 45 (83%) 17 (85%) 27(82%) 46 (84%) ns
Weight (kg) 16.97 ± 3.51 17.28 ± 4.17 16.65 ± 3.08 17.06 ± 4.5 ns
Height (cm) 102.7 ± 8.3 101.9 ± 8.3 102.9 ± 8.3 101.96 ± 11.1 ns
BMI (kg/m2) 15.94 ± 1.71 16.4 ± 1.67 15.67 ± 1.73 16.16 ± 1.74 ns
Battelle test 55.69 ± 13.8 47.05 ± 10.33 60.96 ± 13.29 0.002*
CARS test 32.6 ± 7.29 35.9 ± 8.12 30.6 ± 6.11 0.009*
PDBBI test 48.86 ± 10.82 53.93 ± 10.39 46.13 ± 10.47 0.023*
ASD, autism spectrum disorders; AMR, mental regression group; ANMR, non-mental regression group; BMI, body mass index; CARS, Childhood Autism Rating Scale Test; PDDBI,
PDD Behavior Inventory. ns, no significant difference between ASD vs. control and AMR and ANMR. P* value between AMR vs. ANMR. Data are given as the mean ± standard deviation
and median (interquartile range). P-values were obtained from the Mann-Whitney U-test, Student’s T test, or the Fisher exact test, as appropriate. P value ASD P < 0.05 value was
considered to be statistically significant.
TABLE 2 | Plasma cytokine levels in patients with childhood autism (ASD)
compared to the levels in the healthy control group.
Biochemical
biomarkers
n ASD n Control p
C-CRP (mg/L) 54 1.9 ± 4.7 54 2.09 ± 5.09 0.77
Cathepsin D (ug/L) 54 119.5 (81.07–165.4) 54 107.2 (79.1–165.5) 0.874
IL1β (pg/ml)a 9 1.08 (0.6–3.07) 4 2.16 (1.2–4.24) 0.825
IL6 (pg/ml) 44 1.38 (0.34–2.98) 54 0.7 (0.24–1.46) 0.148
IL8 (pg/ml) 52 1.84 (0.84–3.82) 54 1.34 (0.67–2.77) 0.171
TNFα (pg/ml) 54 3.16 (2.2–4.56) 54 2.66 (1.83–3.69) 0.07
MPO (ug/L) 53 80.03 (54.96–148.5) 54 88.2 (61.4–141.5) 0.551
MCP−1(pg/ml) 54 122.46 (100.8–156.32) 54 117.13 (98.2–141.51) 0.228
RANTES (ug/L) 54 70.97 (41.47–135.8) 54 59.75 (28.95–94.92) 0.175
PAI (ug/L) 54 70.07 (45.52–92.65) 54 62.91 (40.62–111.53) 0.766
NCAM (ug/L) 54 392.20 ± 73.567 54 410.13 ± 72.68 0.196
ICAM (ug/L) 54 173.1 (148.85–189.9) 54 159.9 (143.2–188.6) 0.166
VCAM (ug/L) 54 1083.7 (903.8–1216.8) 54 1047.6 (840.2–1162.48) 0.283
HGF (pg/ml) 54 162.7 (136.1–222.3) 54 163.17 (131.07–194.36) 0.514
BDNF (ug/L) 54 5.04 (2.95–7.62) 54 5.36 (3.48–10.19) 0.825
NGF (pg/ml) 21 4.78 (2.93–13.18) 16 2.06 (1.25–7.36) 0.05
BDNF, brain-derived neurotrophic factor; C-CRP, C-reactive protein; HGF, hepatocyte
growth factor; ICAM, intercellular adhesion molecule; IL, interleukin; MCP-1, monocyte
chemotactic protein; MPO, myeloperoxidase; NCAM, neuronal cell adhesion molecule;
NGF, nerve growth factor; PAI, plasminogen activator factor; RANTES, regulated on
activation normal t cell expressed and secreted; TNFα, tumor necrosis factor α; VCAM,
vascular cell adhesion molecule.
Data are given as the mean ± SD or median values interquartile range. P-values
were obtained from the Mann-Whitney U-test or Student’s T-test, as appropriate using
Bonrrefoni correction. P < 0.05 was considered to be statistically significant. P-values in
bold are statistically significant.
Associations between plasma chemokine levels and clinical
behavioral and developmental outcomes were studied.
Only correlations with r > 0.3 are shown in Table 3. No
associations between the scores obtained in behavioral
and developmental tests and the cytokines in the ASD
group were observed. However, within the ASD group, the
ANMR subgroup exhibited a negative correlation between
ICAM and language and social communication scores.
In the AMR subgroup, some inflammatory parameters
showed an association with repetitive behavior (MPO and
RANTES), stereotypes (IL8), and social interaction scores
(IL6).
DISCUSSION
The study results show that there are no significant differences
between the levels of cytokines, cell adhesion molecules
or growth factors in ASD children compared to those in
typically-developing children. Nevertheless, in the ANMR
subgroup of autistic children, lower plasma levels of the
NCAM adhesion molecule were detected compared to
the levels in the AMR subgroup and the control group.
This ANMR group also exhibited higher NGF levels than
the typically-developing children, which could indicate an
alteration in neuronal development. These results seem to
confirm the great heterogeneity of autism and the need to
differentiate the pathophysiological pathways to define the
phenotype spectrum and more specific and individualized
therapies.
In addition to the established criteria of DMS-5 and the
use of ADOS 2 for the diagnostic assessment of patients
with ASD, other complementary tests were performed to
evaluate the developmental level and the severity of the autistic
symptomatology. These included the Battelle Developmental
Inventory, PDDBI-Parent Ratings and CARS-2. These tests were
instrumental in the identification of clinical characteristics
in the ASD neurodevelopmental regression subgroup
and ASD-diagnosed children without neurodevelopmental
regression.
The immunological role in the etiopathogenesis of ASD is a
matter of ongoing debate among researchers. There is evidence of
an alteration in the immune system of children with ASD, which
includes increased cytokine levels in both the brain and plasma
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FIGURE 1 | The neuronal cell adhesion molecule (NCAM) and nerve growth factor (NGF) plasma levels in children with autism subdivided as follows: AMR (mental
regression group), ANMR (non-mental regression group) and a healthy control group.
TABLE 3 | Significant correlations between plasma biomarker levels and
behavioral impairments and associated quantitative clinical traits.
Autism Spectrum Disorders ANMR AMR







ADOS Stereotypes r: 0.84
p: 0.01






AMR, mental regression group; ANMR, non-mental regression group; ICAM, intercellular
adhesion molecule; MPO, myeloperoxidase; IL8, interleukin 8; MCP-1, monocyte
chemotactic protein. ADOS, Autism Diagnostic Observation Schedule; CARS, Childhood
Autism Rating Scale Test; PDDBI, PDD Behavior Inventory; EXPRESS, Expressive
language; EXSCA, expressive social communication abilities composite; REPRITC,
repetitive, ritualistic and pragmatic problems composite. SOCAPP, Social Approach
Behaviors.
(14, 26). This theory of immunological alteration is based on the
knowledge that the brain is able to recognize cytokines, such as
the proinflammatory cytokines IL-1a, IL-1β, TNF-α, and IL-6, as
molecular signals of sickness (27). The immune system and the
nervous system are in constant two-way communication, with
each exerting a degree of control over the other (28).
Although many studies have reported altered levels of
immune-related biomarkers or abnormal immune function in
ASD, it has been surprisingly difficult to identify a consistent
pattern of immunological alteration across the various studies,
or develop a pathophysiological description of this alteration.
For example, Onore et al. (29), have reported increased levels of
proinflammatory cytokines (IL-1β, IL-6, IL-8, IL-12, p40), as well
as macrophage migration inhibitory factor and platelet-derived
growth factor (PDGF) in patients with autism. El-Ansary et al.
(30) reported that Saudi patients with autism have markedly
higher plasma HSP70, TGF-β2, Caspase-7, and INF-γ levels
compared to age and gender-matched controls. Other authors
have also reported that children with ASD showed altered
levels of immunological parameters, including CCL2, CCL5,
and CXCL9 levels, compared to healthy children (31). Recently,
findings showing increased levels of S100B and TNFα in patients
with ASD have been published (26). Xie et al. (25) have also
observed increased blood TNFα concentrations associated with
symptom severity. Indeed, the levels of TNFα in the Xie autism
group showed a tendency toward significance (p: 0.07). It is
possible therefore that the statistical significance would tend to
increase if the protocol were replicated in a larger sample.
Other authors (32) by contrast, as in the present study, have
found no difference between the cytokine levels of children with
ASD and those of typically-developing children. For example,
Napolini et al. (33) observed no increase in cytokines in a
batch of up to 40 inflammatory parameters in the peripheral
blood of children with ASD aged 6–8, and evidence that the
immune profiles of children with ASD did not differ from
those of their typically-developing siblings. Ashwood et al. (14)
in an in vitro study and Guloksuz et al. (26) in their plasma
studies also reported no differences in cytokine levels comparing
different subtypes of ASD. These results cannot support a direct
relation between an inflammatory status and ASD. However,
an etiopathogenic implication of an immunological activation
during the prenatal period has been described (34), but peripheral
blood cytokine measurements may not directly correlate with
changes in the central nervous system.
Cathepsin D, a protease abundantly expressed in the brain,
can trigger apoptosis and secretion of cytokines, including IL-
4, IL-8, IL-10, and IL-13. Malik et al. (35) have reported an
increase in cathepsin D, and the corresponding increase in
proinflammatory cytokines (TNFα-and IL-6) and apoptosis in
autistic lymphoblasts, suggesting that cathepsin D may play an
important role in cytokine-induced apoptosis. However, this
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study was conducted using a small sample of six children with
ASD and was an in vitro study, which may account for the
differences with the present findings.
Immune globulin-like cell adhesion molecules (CAMs)
constitute a broad family, including NCAM, sICAM-1 and
vCAM-1, required for tissue formation, maintenance and
function. NCAM is related to a dynamic connection between
cells, and decreased plasma levels of children with ASD compared
to those in age-matched controls have been reported. This finding
emphasizes the difference with other psychiatric pathologies,
such as schizophrenia, in which these levels are elevated (36).
However, other studies have found that NCAM mRNA levels
were not altered in either serum samples or postmortem brain
samples (37) taken from children with ASD. Jovanova-Nesic et al.
(38) have also observed a decrease in the expression of NCAM-1
in the CA1 and CA3 fields of the hippocampus and, to a lesser
extent, in the basal ganglia, limbic structures and cervical spinal
cord.
A protective effect of glial cell line-derived neurotrophic
factor (GDNF) on injured DA cells has been shown through
its influence on NCAM (39). In the present study, a decrease
in NCAM levels was detected in the ANMR subgroup; this
may point to an incident having taken place at an earlier time,
possibly during the early stages of embryonic development. The
first years of development are known to be crucial for the
formation of neural circuits, when there is a high predisposition
to interruption. CAMs play a crucial role in many aspects of
neural circuit formation and an alteration in these molecules can
lead to an alteration in neuronal growth and synaptogenesis.
The plasma levels of VCAM and ICAM have been studied in
high-functioning adults with ASD, revealing a decrease in the
former molecule and normal levels of the latter (40). Similar
results have been observed in other patients with ASD (17).
However, the present study, focusing on the plasma levels of
children with ASD aged 2-6, did not detect any such anomalies.
There are multiple lines of evidence indicating that immune
responses and CAM levels correlate to the severity of behavioral
impairments and associated symptoms and quantitative clinical
traits (13, 14). Thus, dysregulation of IL-1 is implicated
in impairments in memory and learning, and increases
in MIP-1α, MIP-1β, and IP-10 are significantly associated
with social behavior (16). Furthermore, disrupting NCAM
has been shown to lead to several memory and learning
deficits. In the present study, the levels of the biological
parameters studied differed between the children with ASD
who exhibited neurodevelopmental regression and those
who did not show regression, suggesting an association
between the parameters and behavioral/developmental
outcomes. This finding supports the theory of different
pathophysiological pathways with an earlier incident in
the ANMR subgroup, as opposed to a possible subsequent
aggression during the early stages of life in the AMR subgroup,
something that requires clarification in future research.
However, the significant association of cytokine levels with
quantitative traits and the clinical subgroups analyzed suggests
that altered immune responses may affect the core ASD
characteristics.
An increasing body of evidence indicates that growth factors
modulate motor, emotional and cognitive functions, which may
explain several clinical manifestations of these disorders (41).
The results regarding plasma levels of BDNF in patients with
ASD (24, 42, 43) are inconsistent. BDNF, which is the most
abundant neurotrophin in the CNS, can cross the blood-brain
barrier, and levels in plasma and brain are highly correlated.
Other growth factors have not been investigated as widely. NGF is
also a member of the neurotrophin family and is involved in the
growth, differentiation, survival and regeneration of nerve cells
by stimulating Trk A (a transmembrane tyrosine kinase) and p75
receptors. NGF is primarily present in highly functional brain
regions (41). In line with the present authors, other researchers
have observed increased levels of NGF in children with ASD
(44) and hyperactivity (45). In the present study, NGF was
detected in fewer than 50% of the children with ASD and
typically-developing children, which may be related to the early
stage of life, or the sensitivity of the analysis. Second, increased
NGF levels were observed in the ANMR subgroup, which also
exhibited decreased levels of NCAM. Thus, although we did not
observe an inverse association between these two molecules in
the ANMR subgroup, the enhancement in NGF levels after brain
disruption may be a part of a neuronal recovery process. This
mechanism is possibly similar to the one related to NCAM and
GDNF (39). HGF seems to be particularly active in the nervous
system, and it plays a significant role in the neurodevelopmental
process, including synapse formation (46). Significantly low
levels of HGF have been described in high-functioning children
with ASD (47). An association has been described between HGF
serum levels and the presence of gastrointestinal disease, which
is sometimes linked to ASD in subgroups of children (48). In our
study, no differences were identified in the group of children with
ASD.
The present observational case-control study has certain
limitations. Given that the prevalence of ASD is 1%, 50 patients
with ASD needed to be recruited to the study; an advantage is
that clinical variability is avoided when the study is performed
in a single hospital with a strict protocol and very restrictive
inclusion and exclusion criteria. It is impossible to know whether
the variations detected in the ASD group are a cause or a
consequence of the disorder. Such highly varying results may
be accounted for not only by the differences in the way this
study was approached but also by the natural heterogeneity
of ASD, which is still not well understood. However, this
study benefits from a careful selection of children of similar
ages, as well as the complete diagnosis of ASD with multiple
tests, clinical follow-up and associated complementary tests.
In addition, none of the ASD children were undergoing any
concomitant treatment shown to modify the plasma levels
of the molecules being measured. Discrepancies within the
authors’ results may be partly explained by the different
techniques used for analysis, as the ELISA and RIAC assays
are more sensitive than the Luminex assay; however, the latter
allows the measurement of more analytes with a minimal
volume.
In conclusion, the results of this study show that there is not
a typical profile for the expression of relevant plasma cytokines,
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adhesion molecules or growth factors in children with ASD
compared with that in typically-developing children. However,
in the ANMR and AMR subgroups, some of the adhesion
molecules and neuronal growth factors that could be involved
in an early alteration in neurodevelopment exhibited differences.
ASD is a heterogeneous pathology that converges in different
ASD phenotypes; the key biomarkers in the etiology of ASD,
which remains unknown, must therefore be subjected to further
investigation.
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